Tags

Type your tag names separated by a space and hit enter

Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?
Trends Pharmacol Sci. 2011 Sep; 32(9):562-71.TP

Abstract

Alzheimer's disease (AD) is the most common form of neurodegenerative disease. The vast majority cases of AD are sporadic, without clear cause, and a combination of environmental and genetic factors has been implicated. The hypothesis that homocysteine (Hcy) is a risk factor for AD was initially prompted by the observation that patients with histologically confirmed AD had higher plasma levels of Hcy, termed hyperhomocysteinemia (HHcy), than age-matched controls. Most evidence accumulated so far implicates HHcy as a risk factor for AD onset, but there are also conflicting results. In this review we summarize reports on the relationship between HHcy and AD from epidemiological investigations, including observational studies and randomized controlled clinical trials. We also examine recent in vivo and in vitro studies of potential mechanisms whereby HHcy could influence AD development. Finally, we discuss possible reasons for the existing conflicting data and provide suggestions for future studies.

Authors+Show Affiliations

Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

21684021

Citation

Zhuo, Jia-Min, et al. "Is Hyperhomocysteinemia an Alzheimer's Disease (AD) Risk Factor, an AD Marker, or Neither?" Trends in Pharmacological Sciences, vol. 32, no. 9, 2011, pp. 562-71.
Zhuo JM, Wang H, Praticò D. Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci. 2011;32(9):562-71.
Zhuo, J. M., Wang, H., & Praticò, D. (2011). Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends in Pharmacological Sciences, 32(9), 562-71. https://doi.org/10.1016/j.tips.2011.05.003
Zhuo JM, Wang H, Praticò D. Is Hyperhomocysteinemia an Alzheimer's Disease (AD) Risk Factor, an AD Marker, or Neither. Trends Pharmacol Sci. 2011;32(9):562-71. PubMed PMID: 21684021.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? AU - Zhuo,Jia-Min, AU - Wang,Hong, AU - Praticò,Domenico, Y1 - 2011/06/20/ PY - 2011/03/16/received PY - 2011/05/11/revised PY - 2011/05/12/accepted PY - 2011/6/21/entrez PY - 2011/6/21/pubmed PY - 2011/12/15/medline SP - 562 EP - 71 JF - Trends in pharmacological sciences JO - Trends Pharmacol Sci VL - 32 IS - 9 N2 - Alzheimer's disease (AD) is the most common form of neurodegenerative disease. The vast majority cases of AD are sporadic, without clear cause, and a combination of environmental and genetic factors has been implicated. The hypothesis that homocysteine (Hcy) is a risk factor for AD was initially prompted by the observation that patients with histologically confirmed AD had higher plasma levels of Hcy, termed hyperhomocysteinemia (HHcy), than age-matched controls. Most evidence accumulated so far implicates HHcy as a risk factor for AD onset, but there are also conflicting results. In this review we summarize reports on the relationship between HHcy and AD from epidemiological investigations, including observational studies and randomized controlled clinical trials. We also examine recent in vivo and in vitro studies of potential mechanisms whereby HHcy could influence AD development. Finally, we discuss possible reasons for the existing conflicting data and provide suggestions for future studies. SN - 1873-3735 UR - https://www.unboundmedicine.com/medline/citation/21684021/Is_hyperhomocysteinemia_an_Alzheimer's_disease__AD__risk_factor_an_AD_marker_or_neither L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-6147(11)00081-2 DB - PRIME DP - Unbound Medicine ER -